Generation of food-grade recombinant Lactobacillus casei delivering Myxococcus xanthus prolyl endopeptidase

被引:23
作者
Alvarez-Sieiro, Patricia [1 ]
Cruz Martin, Maria [1 ]
Redruello, Begona [1 ]
del Rio, Beatriz [1 ]
Ladero, Victor [1 ]
Palanski, Brad A. [2 ,3 ]
Khosla, Chaitan [2 ,3 ]
Fernandez, Maria [1 ]
Alvarez, Miguel A. [1 ]
机构
[1] CSIC, IPLA, Villaviciosa 33300, Asturias, Spain
[2] Stanford Univ, Dept Chem, Stanford, CA 94305 USA
[3] Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA
关键词
Celiac disease; Gluten; Prolyl endopeptidase; Myxococcus xanthus; Heterologous expression; Lactobacillus casei; LACTIC-ACID BACTERIA; AGGREGATION-PROMOTING FACTOR; CELIAC-DISEASE; MOUSE MODEL; IN-VITRO; GLUTEN; EXPRESSION; PROTEINS; SURVIVAL; STRAINS;
D O I
10.1007/s00253-014-5730-7
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Prolyl endopeptidases (PEP) (EC 3.4.21.26), a family of serine proteases with the ability to hydrolyze the peptide bond on the carboxyl side of an internal proline residue, are able to degrade immunotoxic peptides responsible for celiac disease (CD), such as a 33-residue gluten peptide (33-mer). Oral administration of PEP has been suggested as a potential therapeutic approach for CD, although delivery of the enzyme to the small intestine requires intrinsic gastric stability or advanced formulation technologies. We have engineered two food-grade Lactobacillus casei strains to deliver PEP in an in vitro model of small intestine environment. One strain secretes PEP into the extracellular medium, whereas the other retains PEP in the intracellular environment. The strain that secretes PEP into the extracellular medium is the most effective to degrade the 33-mer and is resistant to simulated gastrointestinal stress. Our results suggest that in the future, after more studies and clinical trials, an engineered food-grade Lactobacillus strain may be useful as a vector for in situ production of PEP in the upper small intestine of CD patients.
引用
收藏
页码:6689 / 6700
页数:12
相关论文
共 55 条
[1]   The site-specific recombination system of the Lactobacillus species bacteriophage A2 integrates in Gram-positive and Gram-negative bacteria [J].
Alvarez, MA ;
Herrero, M ;
Suárez, JE .
VIROLOGY, 1998, 250 (01) :185-193
[2]  
[Anonymous], J APPL MICROBIOL
[3]  
[Anonymous], 1986, BIOCH ED, DOI DOI 10.1016/0307-4412(86)90228-1
[4]  
Axelsson L., 1998, LACTIC ACID BACTERIA, VSecond, P1
[5]   ORAL ENZYME THERAPY FOR CELIAC SPRUE [J].
Bethune, Michael T. ;
Khosla, Chaitan .
METHODS IN ENZYMOLOGY, VOL 502: PROTEIN ENGINEERING FOR THERAPEUTICS, PT A, 2012, 502 :241-271
[6]   The lactic acid bacteria: A literature survey [J].
Carr, FJ ;
Chill, D ;
Maida, N .
CRITICAL REVIEWS IN MICROBIOLOGY, 2002, 28 (04) :281-370
[7]   Review article: probiotics for the treatment of irritable bowel syndrome - focus on lactic acid bacteria [J].
Clarke, G. ;
Cryan, J. F. ;
Dinan, T. G. ;
Quigley, E. M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (04) :403-413
[8]   Monitoring of gluten-free diet compliance in celiac patients by assessment of gliadin 33-mer equivalent epitopes in feces [J].
Comino, Isabel ;
Real, Ana ;
Vivas, Santiago ;
Angel Siglez, Miguel ;
Caminero, Alberto ;
Nistal, Esther ;
Casqueiro, Javier ;
Rodriguez-Herrera, Alfonso ;
Cebolla, Angel ;
Sousa, Carolina .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2012, 95 (03) :670-677
[9]   SURVIVAL OF LACTIC-ACID BACTERIA IN THE HUMAN STOMACH AND ADHESION TO INTESTINAL-CELLS [J].
CONWAY, PL ;
GORBACH, SL ;
GOLDIN, BR .
JOURNAL OF DAIRY SCIENCE, 1987, 70 (01) :1-12
[10]   Mortality in patients with coeliac disease and their relatives:: a cohort study [J].
Corrao, G ;
Corazza, GR ;
Bagnardi, V ;
Brusco, G ;
Ciacci, C ;
Cottone, M ;
Guidetti, CS ;
Usai, P ;
Cesari, P ;
Pelli, MA ;
Loperfido, S ;
Volta, U ;
Calabró, A ;
Certo, M .
LANCET, 2001, 358 (9279) :356-361